Startseite BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation

  • Dhritiman Chakraborty , Sunil Shakya , Sanjana Ballal , Shipra Agarwal und Chandrasekhar Bal EMAIL logo
Veröffentlicht/Copyright: 7. Oktober 2020
Journal of Pediatric Endocrinology and Metabolism
Aus der Zeitschrift Journal of Pediatric Endocrinology and Metabolism Band 33 Heft 11

Abstract

Objectives

The primary objective of this study was to determine the prevalence of BRAFV600E and TERTpromoter mutations in paediatric and young adult patients with papillary thyroid carcinoma (PTC) and the secondary objective, to assess their association with clinicopathological features.

Methods

Patients ≤20 years who underwent surgery for differentiated thyroid cancer (DTC) from 2005 to 2018 were consecutively enrolled for BRAFV600E and TERTpromoter mutations analysis and records analysed for the association of aggressive features. Univariate analysis and multivariate logistic regression were used to identify the independent predictors of BRAFV600E mutations.

Results

Among 100 patients with DTC, 68 patients were ≤18 years and the remaining 30 patients were >18 years of age with a median age of 17 years (IQR 14–19 years) 98 patients had PTC and 2 had FTC. BRAFV600E mutation was present in 14/98 (14.3%) PTC and TERTpromoter mutation noted in none. Multivariate analysis identified RAI refractoriness (OR:10.57, 95% CI: 2.6 to 41.6, P-0.0008) as an independent factor associated with BRAFV600E mutation. 17 patients with distant metastases were negative for both BRAFV600E or TERTpromoter mutation. No significant association was observed between age, gender, PTC variants, extra-thyroidal extension, lymphovascular invasion, multifocality, RAI administration and event rate with BRAFV600E mutation. Irrespective of BRAFV600E mutation, radioiodine refractory status (p-0.0001) had a reduced EFS probability.

Conclusion

In paediatric & young adult PTC, TERTpromoter mutation is absent and BRAFV600E mutation is not associated with distant metastasis. The prevalence rate of the BRAFV600E mutation is much lower compared to adult PTC patients.

Keywords: BRAFV600E mutation; paediatric and young adult; papillary thyroid cancer; TERT mutation; thyroid cancer
Corresponding author: Dr Chandrasekhar Bal, MD, D.Sc. Professor & Head, Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India, Phone: +91 90137 75659, E-mail:

  1. Research funding: This work was funded by a grant from Indian Council of Medical Research (ICMR/5/13/5/2016-NCD-III), Department of Health Research, Govt. of India.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: No funding organizations played a role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

  4. Ethical approval: Ethical clearance was obtained before commencing the study (Ref No: IECPG-448/27.09.2018, RT-17/14.11.2018).

  5. Informed consent: Informed consent was obtained from all individuals included in this study.

References

1. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 1975–2016. Available at: https://seer.cancer.gov/csr/1975_2016/ [Accessed July 2019].Suche in Google Scholar

2. Kumar, A, Bal, CS. Differentiated thyroid cancer. Indian J Pediatr 2003;70:707–13. https://doi.org/10.1007/bf02724312.10.1007/BF02724312Suche in Google Scholar

3. Wu, XC, Chen, VW, Steele, B, Roffers, S, Klotz, JB, Correa, CN. Cancer incidence in adolescents and young adults in the United States, 1992–1997. J Adolesc Health 2003;32:405–15. https://doi.org/10.1016/s1054-139x(03)00057-0.10.1016/S1054-139X(03)00057-0Suche in Google Scholar

4. Neiva, F, Mesquita, J, Paco Lima, S, Matos, MJ, Costa, C, Castro-Correia, C, et al. Thyroid carcinoma in children and adolescents: a retrospective review. Endocrinol Nutr 2012;59:105–8. https://doi.org/10.1016/j.endoen.2011.11.004.10.1016/j.endonu.2011.11.003Suche in Google Scholar

5. Rivkees, SA, Mazzaferri, EL, Verburg, FA, Reiners, C, Luster, M, Breuer, CK, et al. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev 2011;32:798–826. https://doi.org/10.1210/er.2011-0011.10.1210/er.2011-0011Suche in Google Scholar

6. Vassilopoulou-Sellin, R, Klein, MJ, Smith, TH, Samaan, NA, Frankenthaler, RA, Goepfert, H, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993;71:1348–52. https://doi.org/10.1002/1097-0142(19930215)71:4<1348::aid-cncr2820710429>3.0.co;2-3.10.1002/1097-0142(19930215)71:4<1348::AID-CNCR2820710429>3.0.CO;2-3Suche in Google Scholar

7. Bal, CS, Garg, A, Chopra, S, Ballal, S, Soundararajan, R. Prognostic factors in pediatric differentiated thyroid cancer patients with pulmonary metastases. J Pediatr Endocrinol Metab Jul 2015;28:745–51. https://doi.org/10.1515/jpem-2014-0247.10.1515/jpem-2014-0247Suche in Google Scholar

8. Garnett, MJ, Marais, R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313–9. https://doi.org/10.1016/j.ccr.2004.09.022.10.1016/j.ccr.2004.09.022Suche in Google Scholar

9. Nucera, C, Goldfarb, M, Hodin, R, Parangi, S. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 2009;1795:152–61. https://doi.org/10.1016/j.bbcan.2009.01.003.10.1016/j.bbcan.2009.01.003Suche in Google Scholar

10. Carlomagno, F, Anaganti, S, Guida, T, Salvatore, G, Troncone, G, Wilhelm, SM, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326–34. https://doi.org/10.1093/jnci/djj069.10.1093/jnci/djj069Suche in Google Scholar

11. Kim, SJ, Lee, KE, Myong, JP, Park, JH, Jeon, YK, Min, HS, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 2012;36:310–7. https://doi.org/10.1007/s00268-011-1383-1.10.1007/s00268-011-1383-1Suche in Google Scholar

12. Takacsova, E, Kralik, R, Waczulikova, I, Zavodna, K, Kausitz, J. A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer. Neoplasma 2017;64:156–64. https://doi.org/10.4149/neo_2017_120.10.4149/neo_2017_120Suche in Google Scholar PubMed

13. Czarniecka, A, Oczko-Wojciechowska, M, Barczyński, M. BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg 2016;5:495–505. https://doi.org/10.21037/gs.2016.09.09.10.21037/gs.2016.09.09Suche in Google Scholar PubMed PubMed Central

14. Brzeziańska, E, Pastuszak-Lewandoska, D, Wojciechowska, K, Migdalska-Sek, M, Cyniak-Magierska, A, Nawrot, E, et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett 2007;28:351–9. PMID: 17693984.Suche in Google Scholar

15. Fugazzola, L, Puxeddu, E, Avenia, N, Romei, C, Cirello, V, Cavaliere, A, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13:455–64. https://doi.org/10.1677/erc.1.01086.10.1677/erc.1.01086Suche in Google Scholar PubMed

16. Kim, TY, Kim, WB, Song, JY, Rhee, YS, Gong, G, Cho, YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2005;63:588–93. https://doi.org/10.1111/j.1365-2265.2005.02389.x.10.1111/j.1365-2265.2005.02389.xSuche in Google Scholar PubMed

17. Givens, DJ, Buchmann, LO, Agarwal, AM, Grimmer, JF, Hunt, JP. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope 2014;124:E389–93. https://doi.org/10.1002/lary.24668.10.1002/lary.24668Suche in Google Scholar PubMed

18. Nikita, ME, Jiang, W, Cheng, SM, Hantash, FM, McPhaul, MJ, Newbury, RO, et al. Mutational analysis in pediatric thyroid cancer and correlations with age, ethnicity, and clinical presentation. Thyroid 2016;26:227–34. https://doi.org/10.1089/thy.2015.0401.10.1089/thy.2015.0401Suche in Google Scholar PubMed PubMed Central

19. Ballester, LY, Sarabia, SF, Sayeed, H, Patel, N, Baalwa, J, Athanassaki, I, et al. Integrating molecular testing in the diagnosis and management of children with thyroid lesions. Pediatr Dev Pathol 2016;19:94–100. https://doi.org/10.2350/15-05-1638-oa.1.10.2350/15-05-1638-OA.1Suche in Google Scholar PubMed

20. Yamashita, S, Saenko, V. Mechanisms of Disease: molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab 2007;3:422–9. https://doi.org/10.1038/ncpendmet0499.10.1038/ncpendmet0499Suche in Google Scholar PubMed

21. Penko, K, Livezey, J, Fenton, C, Patel, A, Nicholson, D, Flora, M, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005;15:320–5. https://doi.org/10.1089/thy.2005.15.320.10.1089/thy.2005.15.320Suche in Google Scholar PubMed

22. Kumagai, A, Namba, H, Saenko, VA, Ashizawa, K, Ohtsuru, A, Ito, M, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4280–4. https://doi.org/10.1210/jc.2004-0172.10.1210/jc.2004-0172Suche in Google Scholar PubMed

23. Liu, C, Liu, Z, Chen, T, Zeng, W, Guo, Y, Huang, T. TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: a meta-analysis. Sci Rep 2016;6:36990. https://doi.org/10.1038/srep36990.10.1038/srep36990Suche in Google Scholar PubMed PubMed Central

24. Su, X, Jiang, X, Wang, W, Wang, H, Xu, X, Lin, A, et al. Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis. Onco Targets Ther 2016;9:6965–76. https://doi.org/10.2147/ott.s116594.10.2147/OTT.S116594Suche in Google Scholar PubMed PubMed Central

25. Kim, TH, Kim, YE, Ahn, S, Kim, JY, Ki, CS, Oh, Yl, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr Relat Cancer 2016;23:813–23. https://doi.org/10.1530/erc-16-0219.10.1530/ERC-16-0219Suche in Google Scholar PubMed

26. Liu, R, Xing, M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 2016;23:R143–55. https://doi.org/10.1530/erc-15-0533.10.1530/ERC-15-0533Suche in Google Scholar PubMed PubMed Central

27. Geng, J, Wang, H, Liu, Y, Tai, J, Jin, Y, Zhang, J, et al. Correlation between BRAF V600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma. Sci China Life Sci 2017;60:729–38. https://doi.org/10.1007/s11427-017-9083-8.10.1007/s11427-017-9083-8Suche in Google Scholar PubMed

28. Alzahrani, AS, Murugan, AK, Qasem, E, Alswailem, M, Al-Hindi, H, Shi, Y, et al. Single point mutations in pediatric differentiated thyroid cancer. Thyroid 2017;27:189–96. https://doi.org/10.1089/thy.2016.0339.10.1089/thy.2016.0339Suche in Google Scholar PubMed

29. Sobrinho-Simoes, M, Maximo, V, Rocha, AS, Trovisco, V, Castro, P, Preto, A, et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am 2008;37:333–62. https://doi.org/10.1016/j.ecl.2008.02.004.10.1016/j.ecl.2008.02.004Suche in Google Scholar PubMed

30. Ballal, S, Shakya, S, Yadav, MP, Mathur, S, Deo, SVS, Bal, CS. Correlation between BRAF-V600E mutations and clinicopathologic parameters in papillary thyroid cancer: a study in Indian population. Indian J Nucl Med [Abstract] 2016;31:4–4.Suche in Google Scholar

31. Chakraborty, A, Narkar, A, Mukhopadhyaya, R, Kane, S, D’Cruz, A, Rajan, MG. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol 2012;23:83–93. https://doi.org/10.1007/s12022-011-9184-5.10.1007/s12022-011-9184-5Suche in Google Scholar PubMed

32. Henke, LE, Perkins, SM, Pfeifer, JD, Ma, C, Chen, Y, DeWees, T, et al. BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer 2014;61:1168–72. https://doi.org/10.1002/pbc.24935.10.1002/pbc.24935Suche in Google Scholar PubMed

33. Hardee, S, Prasad, ML, Hui, P, Dinauer, CA, Morotti, RA. Pathologic characteristics, natural history, and prognostic implications of BRAFV600E mutation in pediatric papillary thyroid carcinoma. Pediatr Dev Pathol 2017;20:206–12. https://doi.org/10.1177/1093526616689628.10.1177/1093526616689628Suche in Google Scholar PubMed

34. Onder, S, Ozturk Sari, S, Yegen, G, Sormaz, IC, Yilmaz, I, Poyrazoglu, S, et al. Classic architecture with multicentricity and local recurrence, and absence of TERT promoter mutations are correlates of BRAF (V600E) harboring pediatric papillary thyroid carcinomas. Endocr Pathol 2016;27:153–61. https://doi.org/10.1007/s12022-016-9420-0.10.1007/s12022-016-9420-0Suche in Google Scholar PubMed

35. Oishi, N, Kondo, T, Nakazawa, T, Mochizuki, K, Inoue, T, Kasai, K, et al. Frequent BRAF V600E and absence of TERT promoter mutations characterize sporadic pediatric papillary thyroid carcinomas in Japan. Endocr Pathol 2017;28:103–11. https://doi.org/10.1007/s12022-017-9470-y.10.1007/s12022-017-9470-ySuche in Google Scholar PubMed

36. Xing, M, Liu, R, Liu, X, Murugan, AK, Zhu, G, Zeiger, MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014;32:2718–26. https://doi.org/10.1200/jco.2014.55.5094.10.1200/JCO.2014.55.5094Suche in Google Scholar PubMed PubMed Central

37. Alzahrani, AS, Qasem, E, Murugan, AK, Al-Hindi, HN, AlKhafaji, D, Almohanna, M, et al. Uncommon TERT promoter mutations in pediatric thyroid cancer. Thyroid 2016;26:235–41. https://doi.org/10.1089/thy.2015.0510.10.1089/thy.2015.0510Suche in Google Scholar PubMed

38. Lee, C, Lee, KC, Schneider, EB, Zeiger, MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 2012;97:4559–70. https://doi.org/10.1210/jc.2012-2104.10.1210/jc.2012-2104Suche in Google Scholar PubMed PubMed Central

39. Monaco, SE, Pantanowitz, L, Khalbuss, WE, Benkovich, VA, Ozolek, J, Nikiforova, MN, et al. Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration. Cancer Cytopathology 2012;120:342–50. https://doi.org/10.1002/cncy.21199.10.1002/cncy.21199Suche in Google Scholar PubMed

40. Mitsutake, N, Knauf, JA, Mitsutake, S, Mesa, CJr, Zhang, L, Fagin, JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 2005;65:2465–73. https://doi.org/10.1158/0008-5472.can-04-3314.10.1158/0008-5472.CAN-04-3314Suche in Google Scholar PubMed

41. Saavedra, HI, Knauf, JA, Shirokawa, JM, Wang, J, Ouyang, B, Elisei, R, et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000;19:3948–54. https://doi.org/10.1038/sj.onc.1203723.10.1038/sj.onc.1203723Suche in Google Scholar PubMed

42. Francis, GL, Waguespack, SG, Bauer, AJ, Angelos, P, Benvenga, S, Cerutti, JM, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 2015;25:716–59. https://doi.org/10.1089/thy.2014.0460.10.1089/thy.2014.0460Suche in Google Scholar PubMed PubMed Central

43. Landa, I, Ganly, I, Chan, TA, Mitsutake, N, Matsuse, M, Ibrahimpasic, T, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013;98:E1562–6. https://doi.org/10.1210/jc.2013-2383.10.1210/jc.2013-2383Suche in Google Scholar PubMed PubMed Central

44. Liu, X, Bishop, J, Shan, Y, Pai, S, Liu, D, Murugan, AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013;20:603–10. https://doi.org/10.1530/erc-13-0210.10.1530/ERC-13-0210Suche in Google Scholar PubMed PubMed Central

45. Gandolfi, G, Ragazzi, M, Frasoldati, A, Piana, S, Ciarrocchi, A, Sancisi, V TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol 2015 Apr;172:403–13. https://doi.org/10.1530/eje-14-0837.10.1530/EJE-14-0837Suche in Google Scholar PubMed

46. Liu, J, Liu, R, Shen, X, Zhu, G, Li, B, Xing, M. The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts the loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nucl Med 2020 Feb;61:177–82. https://doi.org/10.2967/jnumed.119.227652.10.2967/jnumed.119.227652Suche in Google Scholar PubMed PubMed Central

47. Melo, M, Rocha, AG, Batista, R, Vinagre, J, Martins, MJ, Costa, G, et al. TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease. J Clin Endocrinol Metab 2017 Jun 1;102:1898–907. https://doi.org/10.1210/jc.2016-2785. PMID: 28323937.10.1210/jc.2016-2785Suche in Google Scholar PubMed

48. Sassolas, G, Hafdi-Nejjari, Z, Ferraro, A, Decaussin-Petrucci, M, Rousset, B, Borson-Chazot, F, et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid 2012;22:17–26. https://doi.org/10.1089/thy.2011.0215.10.1089/thy.2011.0215Suche in Google Scholar PubMed

49. Rivera, G, Lugo-Vicente, H. Thyroid cancer in children. Bol Asoc Med P R 2014;106:48–54. https://doi.org/10.3390/genes10090723. PMID: 31540418.10.3390/genes10090723Suche in Google Scholar PubMed PubMed Central

Received: 2020-04-05
Accepted: 2020-09-13
Published Online: 2020-10-07
Published in Print: 2020-11-26

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Review Article
  3. The influence of growth hormone therapy on the cardiovascular system in Turner syndrome
  4. Original Articles
  5. Clinical utility of urinary gonadotrophins in hypergonadotrophic states as Turner syndrome
  6. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children
  7. Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment
  8. Mechanisms and early patterns of dyslipidemia in pediatric type 1 and type 2 diabetes
  9. Frequency of thyroid dysfunction in pediatric patients with congenital heart disease exposed to iodinated contrast media – a long-term observational study
  10. Effect of growth hormone therapy on thyroid function in isolated growth hormone deficient and short small for gestational age children: a two-year study, including on assessment of the usefulness of the thyrotropin-releasing hormone (TRH) stimulation test
  11. Clinical relevance of T lymphocyte subsets in pediatric Graves’ disease
  12. Long-term follow-up of differentiated thyroid carcinoma in children and adolescents
  13. A quality improvement project for managing hypocalcemia after pediatric total thyroidectomy
  14. Pubertal development and adult height in patients with congenital hypothyroidism detected by neonatal screening in southern Brazil
  15. Clinical characteristics, surgical approach, BRAFV600E mutation and sodium iodine symporter expression in pediatric patients with thyroid carcinoma
  16. BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation
  17. Case Reports
  18. Pseudohypoparathyroidism type 1B (PHP1B), a rare disorder encountered in adolescence
  19. Impaired glucose homeostasis and a novel HLCS pathogenic variant in holocarboxylase synthetase deficiency: a report of two cases and brief review
  20. Transcobalamin II deficiency in twins with a novel variant in the TCN2 gene: case report and review of literature
  21. Aldosterone deficiency with a hormone profile mimicking pseudohypoaldosteronism
  22. Non-classical lipoid adrenal hyperplasia presenting as hypoglycemic seizures
https://doi.org/10.1515/jpem-2020-0174
Schlagwörter für diesen Artikel
BRAFV600E mutation; paediatric and young adult; papillary thyroid cancer; TERT mutation; thyroid cancer

Artikel in diesem Heft

  1. Frontmatter
  2. Review Article
  3. The influence of growth hormone therapy on the cardiovascular system in Turner syndrome
  4. Original Articles
  5. Clinical utility of urinary gonadotrophins in hypergonadotrophic states as Turner syndrome
  6. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children
  7. Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment
  8. Mechanisms and early patterns of dyslipidemia in pediatric type 1 and type 2 diabetes
  9. Frequency of thyroid dysfunction in pediatric patients with congenital heart disease exposed to iodinated contrast media – a long-term observational study
  10. Effect of growth hormone therapy on thyroid function in isolated growth hormone deficient and short small for gestational age children: a two-year study, including on assessment of the usefulness of the thyrotropin-releasing hormone (TRH) stimulation test
  11. Clinical relevance of T lymphocyte subsets in pediatric Graves’ disease
  12. Long-term follow-up of differentiated thyroid carcinoma in children and adolescents
  13. A quality improvement project for managing hypocalcemia after pediatric total thyroidectomy
  14. Pubertal development and adult height in patients with congenital hypothyroidism detected by neonatal screening in southern Brazil
  15. Clinical characteristics, surgical approach, BRAFV600E mutation and sodium iodine symporter expression in pediatric patients with thyroid carcinoma
  16. BRAFV600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation
  17. Case Reports
  18. Pseudohypoparathyroidism type 1B (PHP1B), a rare disorder encountered in adolescence
  19. Impaired glucose homeostasis and a novel HLCS pathogenic variant in holocarboxylase synthetase deficiency: a report of two cases and brief review
  20. Transcobalamin II deficiency in twins with a novel variant in the TCN2 gene: case report and review of literature
  21. Aldosterone deficiency with a hormone profile mimicking pseudohypoaldosteronism
  22. Non-classical lipoid adrenal hyperplasia presenting as hypoglycemic seizures
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 14.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2020-0174/html?lang=de
Button zum nach oben scrollen